[Retracted] Additional Benefits Conferred by Endoscopic Sclerotherapy to Liver Cirrhosis Patients Receiving Endoscopic Variceal Ligation

Table 5

The PVP, PVD, PVV, and PVF among the ligation group, the sclerotherapy group, and the combined group before and after treatment.

	PVP	PVD	PVV	PVF
Ligation group (n = 45)	25.37 ± 2.03	13.84 ± 0.47	20.25 ± 4.32	741.82 ± 158.45
Sclerotherapy group (n = 45)	24.85 ± 1.92	14.14 ± 0.51	21.03 ± 4.72	752.36 ± 163.15
Combined group (n = 45)	21.45 ± 1.67	11.43 ± 0.35	19.93 ± 4.22	539.59 ± 128.41
t/P (ligation vs. sclerotherapy)	1.248/0.215	2.902/0.005	0.416/0.818	0.311/0.757
t/P (ligation vs. combined)	10.000/<0.001	27.590/<0.001	0.723/0.356	6.652/<0.001
t/P (sclerotherapy vs. combined)	8.963/<0.001	29.390/<0.001	1.165/0.247	6.875/<0.001